Erol Fikrig

L2 Diagnostics, LLC

NIH Rank #2195
  • R01 Holder
  • Early Career
  • Diverse Portfolio

NIH Funding · FY2024

Total Funding
$3.3M
Fiscal year 2024
Grants Awarded
6
Active NIH grants
National Rank
#2,195
Among 57,894 PIs
First NIH Award
2024
Year of first funding

Funding & rank history

NIH funding totals and national rank by fiscal year.

Single fiscal year on record (FY2024): $3.3M across 6 grants · National rank #2195.

Top grants by award amount

Erol Fikrig's NIH grant portfolio, ranked by award amount.

  • 5R42AI142846-05R42
    A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1
    $980.2K
    award amount
  • 5R01AI158615-04R01
    Mosquito SAMSP1 and SAMSP2 influence the initial stage of Plasmodium infection of mice
    $796.5K
    award amount
  • 5R01AI165499-03R01
    A novel Lyme disease vaccine
    $648.1K
    award amount
  • 1R41AI186794-01R41
    The mosquito salivary protein AgBR1 as vaccine candidate against Chikungunya
    $300K
    award amount
  • 1R41AI186833-01R41
    A novel therapeutic for Lyme arthritis based on a secretory leukocyte protease inhibitor
    $299.9K
    award amount
  • 1R41AI179587-01A1R41
    A Multivalent mRNA Vaccine to Prevent Transmission of Tick-bornePathogens
    $298.4K
    award amount

Affiliations

Institutions that have administered grants for Erol Fikrig.

Career milestones

Key NIH funding milestones over time.

  1. 2024
    First NIH Award
    L2 Diagnostics, LLC
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #2195
  6. 2024
    Entered Top 25% Nationally
    Ranked #2195
  7. 2024
    Multi-Institutional Research
    Awards at 2 institutions